The role of PDCs and Th17 cells is not well understood in the pathogenesis of aGVHD. We evaluated PDC and Th17 cells in skin biopsies of 38 patients at diagnosis of aGVHD. The biopsies were tested by immunohistochemistry for the expression of BDCA2, a typical marker of PDCs. We found an increase of BDCA2 ϩ cells in the skin of the patients with aGVHD. Moreover, we observed a strong expression of the type I IFN-inducible protein Mx1 in the skin of the patients with aGVHD, compared with that of those without it, suggesting that PDCs produce type I IFN. We also analyzed the expression of two Th17 surface markers-CD161 and CCR6 -and ROR␥t, the key transcription factor that orchestrates the differentiation of Th17 cells. Significantly higher numbers of ROR␥t ϩ , CD161 ϩ , and CCR6 ϩ cells were counted in the skin of the patients with aGVHD than in the skin of those who underwent allo-SCT and in whom aGVHD did not develop. This study provides evidence for a role of Th17-mediated responses and a potential new pathophysiological link between PDCs and Th17 in human cutaneous aGVHD.
Introduction
aGVHD after allo-SCT is an exaggerated immune response against alloantigens that involves dysregulation of inflammatory cytokine cascades. The generation of T-cell-mediated alloimmune responses is dependent on antigen presentation, which is a cognate interaction between donor T cells and APCs. PDCs are a rare population of circulating cells specialized in the production of large amounts of type I IFN in response to viral infections [1] . Under steady-state conditions, PDCs are present in the blood stream and secondary lymphoid organs, but are normally absent from most peripheral tissues, including the skin. However, large numbers of PDCs have also been found in the skin of patients with psoriasis [2] . Moreover, it has been demonstrated in mouse models that skin injury can induce rapid infiltration of PDCs and activate them to produce IFN-␣. Also, humans skin injury induces infiltration of PDCs and a type I IFN signature [3, 4] . Very few studies have focused on the characterization of immune cells in the target tissues of acute GVHD, especially for PDCs. In the intestinal mucosa of patients with gastrointestinal aGVHD, our group has recently shown an increase in PDCs that correlated with an increased infiltration by Th17 cells [5] . Previous studies established a major role for type I cytokine-driven effectors in aGVHD pathophysiology [6] . The contribution of Th17 has been investigated in aGVHD mouse models with conflicting results. Thus, Yi et al. [7] reported that IL Ϫ
17A
Ϫ/Ϫ T cells exacerbate aGVHD, whereas other studies of IL-17 or RORC-deficient T cells have shown that Th17 cells contribute to aGVHD [8, 9] . Furthermore, blockade of both Th1 and Th17 differentiation has been shown to be essential for preventing GVHD in mice [10] . In humans, the contribution of Th17 cells to aGVHD pathogenesis remains the subject of considerable debate because of similarly conflicting results. Broady et al. [11] found a low frequency of both circulating IL17-producing cells and tissue-localized Th17 cells in cutaneous aGVHD. Conversely, Dander et al. [12] reported a significant increase of circulating Th17 cells in patients with aGVHD. Moreover, Ratajczak et al. [13] reported that the imbalance between Th17 and regulatory T cells could be correlated with the pathologic grade of aGVHD. Because PDCs have been shown to play a major role in different autoimmune diseases [14] and in triggering proinflammatory as well as Th17-related cytokines [3, 15] , we attempted to characterize the PDCs and proinflammatory immune cells that infiltrate the skin of patients with cutaneous aGVHD.
MATERIALS AND METHODS

Study design
Thirty-eight patients who underwent allo-SCT at the University-Hospital of Nantes from June 2006 through September 2010 were included in the study. Among them, 29 (study group) had a diagnosis of cutaneous aGVHD supported by histologic examination of a skin biopsy performed at the onset of symptoms and before initiation of corticosteroid treatment. The remaining 9 patients volunteered to participate as the non-aGVHD control group. All had undergone allo-SCT, showed no sign or symptom of aGVHD, and had received histologic proof of the absence of cutaneous aGVHD. All the patients were enrolled in clinical research protocols approved by local ethics committees. Written, informed consent was obtained in accordance with the principles of the Declaration of Helsinki. Characteristics of the patients and donors and of allo-SCT are summarized in Table 1 . aGVHD clinical [16] and histologic [17] grading data are summarized in Table 2 . In this series, in all the patients engrafted in both groups, full donor chimerism was achieved at a median of 59 (range, 23-117) days after transplantation. The biopsies were identified by a numerical code; thus, when conducting the morphologic and immunohistochemical studies, the examiner did not know to which group the specimens belonged.
Morphologic studies
One skin biopsy was analyzed for each patient. In the control group, the median time for biopsies was 35 (range, 27-50) days after allo-SCT, and in the aGVHD study group, it was 33 (range, 7-131). The skin biopsies were performed according to standard procedures, and histologic examination was performed on hematoxylin-, eosin-, safran-stained sections (Fig. 1A) . Cutaneous aGVHD was graded according to the system described by Lerner et al. [17] . None of the patients from the control or study groups had evidence of viral infection. 
Immunohistochemical studies
Statistical analysis
Clinical and morphologic data, as well as the number of CD8
, and BDCA2 ϩ cells, were entered into a 
RESULTS
PDCs infiltrated the skin of patients with cutaneous aGVHD and induced type I IFN signaling
In this study, we attempt to determine the proportion of PDCs in skin biopsies of patients with or without aGVHD, by quantification of the expression of BDCA2, a typical marker of PDCs. We observed a significant increase of BDCA2 ϩ PDCs in the dermal infiltrate of the skin of the patients with aGVHD (study group) as compared with the skin of those who underwent allo-SCT and in whom aGVHD signs did not develop (control group; Pϭ0.03) (Fig. 1A, D) . Since PDCs are the specialized producer cells of type I IFN, producing 100 -1000 times more than other cell types [1] , we searched for the presence of a type I IFN signature. For this purpose, we investigated whether skin PDCs were activated to produce type I IFN, by using immunohistochemistry to determine the expression of the type I IFN-inducible protein Mx1 [20] . In the control group without cutaneous aGVHD, a relatively low Mx1 expression was detected in the skin of only 2 (22%) patients, whereas in 25 (86%) of 29 patients with cutaneous aGVHD, Mx1 was expressed by mononuclear cells and endothelial cells in the dermal infiltrate (Pϭ0.002) (Fig. 1B, C, E) . Furthermore, we found a marked correlation between the number of BDCA2 ϩ cells and the intensity of Mx1 expression in each biopsy specimen in the 2 groups of patients. Of note, in the patients without cutaneous aGVHD, the few detectable BDCA2 ϩ PDCs most likely did not secrete significant amounts of type I IFN, as the dermal infiltrate expressed only low levels of Mx1 or none at all (Fig. 1F) . Because it has been demonstrated in mouse models that skin injury induces rapid infiltration of PDCs and activates them to produce IFN-␣ [3, 4] , we assumed, as did Gregorio et al. [3] in humans with psoriasis, that IFN-␣ is produced by PDCs. Conversely, in patients with diagnosed cutaneous aGVHD, even a relatively low number of BDCA2 ϩ PDCs induced type I IFN signaling, as suggested by the strong expression of Mx1 in the dermal infiltrate (Fig. 1G ).
Cytotoxic and effectors T cells in the skin of patients with cutaneous aGVHD
As PDCs have been shown to promote proinflammatory responses in injured skin, we assessed the presence of the cellular effectors usually encountered and previously described in the skin of patients with aGVHD [21] . We found that the number of CD8 ϩ T cells was significantly increased in the dermal infiltrate of the skin in the patients with cutaneous aGVHD, as compared with the control group of without signs of the disease (PϽ0.0001) (Fig. 2 A, D) . The number of cells positive for GrB, a well-established marker of cytotoxic T cells, was also increased in the dermal infiltrate of the skin of the patients with aGVHD, compared with those without it (PϽ0.0006) (Fig. 2B, E) . We found an increased number of T cells that expressed T-bet (the transcription factor characteristic of Th1 cells) in the skin infiltrate of the patients with aGVHD, compared with those without it (PϽ0.0001) (Fig. 2G, H) . We also focused on the analysis of CD30, a cell membrane protein of the tumor necrosis factor (TNFR) superfamily expressed on activated CD3
ϩ T cells and upregulated in T cells when exposed to allogeneic antigens [22] . We observed that the absolute number of CD30 ϩ lymphocytes was significantly higher in the dermal infiltrate of the skin of the patients with aGVHD, compared with those without it (Pϭ0.005) (Fig. 2C, F) . Thus, the accumulation of cytotoxic and activated CD30 ϩ T cells reflected an activated immune status in the skin of the patients with aGVHD. 
Th17 cells infiltrated the skin of patients with cutaneous aGVHD
Results in mouse studies have suggested that Th17 cells are critical in the skin injury that occurs in aGVHD [9, 23] . Also, mouse studies have shown that PDC depletion before skin injury inhibits type-17 cytokines, including IL-17 and -22 [3] . Thus, we hypothesized that Th17 cells would preferentially accumulate in the skin of the patients with aGVHD. For the purpose of Th17 cell identification, we used the mucosal chemokine receptor CCR6 [24] and the C-type lectin-like receptor CD161, which are both wellestablished markers of human Th17 cells [25] . Thus, we could show that the absolute number of CD161 ϩ and CCR6 ϩ cells was significantly higher in the dermal infiltrate of the skin of the patients with aGVHD than in those without it (PϽ0.0001 and Pϭ0.01, respectively) ( Fig. 3 A, B, D, E) . To further confirm Th17 cell infiltration, we also assessed the expression of ROR␥t, the key transcription factor that orchestrates the differentiation of Th17 cells [26] . In keeping with the increase in CCR6 ϩ and CD161 ϩ cells, ROR␥t ϩ cells (with nuclear staining) were significantly increased in the skin infiltrate of the patients with aGVHD, when compared with those without it (Pϭ0.001) (Fig. 3C, F ).
DISCUSSION
The current study sheds light on the role of PDCs and Th17 cells in the context of cutaneous aGVHD. Using well-established, specific markers, we showed that in the skin of patients with aGVHD, compared with that of patients without it, the number of BDCA2
ϩ PDCs was significantly increased; the infiltration of the skin by PDCs was associated with a type-I IFN signature; and the number of ROR␥t ϩ infiltrating cells increased significantly.
At present, the controversy continues regarding the role of Th17 cells in the pathogenesis of human aGVHD. Ratajczak et al. [13] focused on gastrointestinal aGVHD and did not find an association between CD4 shown that IL-17 production could be shut off in the course of inflammatory immune responses [27] . Also, one should acknowledge that different conditioning and immunosuppressive regimens, stem cell sources, and disease features may explain the differences between the studies. In our study, we elected not to use skin biopsies from healthy controls, but rather from patients without aGVHD who had undergone allo-SCT, to create the optimal comparative setting by avoiding biases such as the use of systemic immunosuppressive therapy in only one arm of the cohort. Broady et al. [11] did not find an association between Th17 cells and the onset of human cutaneous aGVHD. However, they examined only 7 cases and used very specific experimental conditions, including in vitro culture of dermal cells. It is not clear whether alloreactive Th17 cells would maintain their phenotype after 3 weeks of culture, especially in the absence of polarizing cytokines, which were not added. Indeed, the Th17 phenotype is unstable, and Th17 cells may convert to Th1 cells after a long-term culture period [28] . Van der Waart et al. [29] recently published that functional CD161 ϩ CCR6 ϩ coexpressing T cells disappear from the circulation and home to GVHD-affected tissue sites. Our study confirms and strengthens the results of analyses of the expression of ROR␥t, the key transcription factor of Th17 cells. However, in this study, we could not exclude the possibility that ROR␥t ϩ cells are not truly Th17 cells. Indeed, a skin-invading population of innate lymphocytes and ␥␦ T cells expressing ROR␥t has been identified in an experimental psoriasis model and is involved in the initiation of psoriatic plaque formation [30] . It remains to be established whether such cell populations are involved in human diseases. Our results suggest a potential new pathophysiological link between PDCs and the Th17 response, in the context of cutaneous aGVHD, most likely through the production of type I IFN. Our group has published a report that PDC levels were decreased in the blood of patients with aGVHD [31] , and our results provide evidence that this decrease is related to infiltration of aGVHD target tissues by PDCs. Our findings support a cutaneous aGVHD induction model that can mimic data from autoimmune diseases, where recruited PDCs in GVHD target tissues after local damage (e.g., a conditioning regimen) can promote the production of Th17 cytokines, as the induction of Th17-related cytokines is abrogated in PDC-depleted mice [3, 4] . This is consistent with studies showing that PDCs can drive the differentiation of Th17 cells [15] . Moreover, type I IFN produced by PDCs after stimulation with a TLR7 agonist could drive Th17 responses in vivo [32] .
In our study, we also assessed the presence of CD30 ϩ T cells in the skin of patients with cutaneous aGVHD. CD30 is preferentially expressed by activated or memory Th cells, and its ligand (CD30L; CD153) belongs to the TNF superfamily and is expressed on a large spectrum of immune cells, including PDCs [33] . Studies in mice indicated that the CD30/CD30L interaction could contribute to the CD4 ϩ T cell-mediated aGVHD, as the number of CD4 ϩ T cells in aGVHD target organs decreased when the CD30/CD30L interaction was blocked [34] . To our knowledge, this is the first demonstration of the infiltration of the skin by CD30 ϩ T cells in cutaneous aGVHD. This result is in accordance with those of Chen et al. [35] showing an increase of CD30 ϩ T cells in the blood and in the intestinal mucosa of patients with gastrointestinal aGVHD. Although CD30 is normally expressed on the well-known Th1 and Th2 cells, a recent study in mice showed that not only is CD30 expressed on Th17 cells, but also that the CD30 -CD30L interaction plays a critical role in the differentiation of these cells [36] . Thus, the functional consequences of the interaction of CD30 ϩ T cells with PDCs remain to be investigated in the context of aGVHD. Furthermore, the finding that CD30 ϩ T cells infiltrate the skin in cutaneous aGVHD is an encouraging result, given that several clinical trials evaluating the effectiveness of brentuximab vedotin, a CD30-specific antibody-conjugated drug, in aGVHD prophylaxis are currently ongoing. Although the exact mechanism that links type I IFN production to PDC-mediated Th17 responses is still unclear in aGVHD, data described in this paper do not contradict the established role of Th1 cells in aGVHD pathophysiology [21] . In fact, human Th17 cells may exhibit a close developmental relationship with Th1 cells [28] . A likely scenario would involve AMPs, which bind extracellular self-DNA fragments into aggregated particles that enter PDCs and trigger robust type I IFN production [37] . Of note, the AMP elafin is increased in the skin biopsies and serum of patients with aGVHD [38] . Persistent overexpression of these AMPs may lead to uncontrolled type I IFN responses, as already reported in some autoimmune diseases [28, 39] .
CONCLUSIONS
In conclusion, our study provides a framework for a role for PDCs and Th17-mediated responses in human cutaneous aGVHD, raising the prospect of future innovative approaches to optimizing immunosuppression regimens for the treatment or prophylaxis of aGVHD by targeting PDCs and the Th17 response. Our findings thus support a compelling rationale for designing clinical trials in this setting, based on a current trial aiming to block the Th17 response by using anti-IL-17 monoclonal antibodies in autoimmune diseases [40] . 
